Today, Cartherics proudly hosted a Frocktober Afternoon Tea in support of ovarian cancer awareness and research. Frocktober is a meaningful initiative that encourages us to go the extra style mile – turning heads, starting conversations, and raising vital funds for ovarian cancer research.

We were honoured to welcome Robin Penty, CEO of the Ovarian Cancer Research Foundation, as our guest speaker. Robin’s powerful voice and deep commitment to this cause were both inspiring and deeply moving. Her insights served as a strong reminder of why events like Frocktober matter and highlighted the ongoing need for innovative and effective treatments to improve outcomes for those affected by ovarian cancer.

Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product, for which the first clinical indication will be relapsed and refractory ovarian cancer.

Ovarian cancer (OC) is the most lethal gynaecological cancer, with approximately 1,815 Australian women expected to be diagnosed this year alone. Tragically, only 49% will survive beyond five years. Without urgent action, cases are projected to rise by 66% in our region over the next 25 years.

Cartherics’ CEO, Prof. Alan Trounson said: “We are concerned that progress has been slow to transform into effective therapies for ovarian cancer – we are hoping that new immune cell therapies will make this difference as they enter clinical trials next year.”

By participating in Frocktober, we’re helping to raise vital awareness and funds for life-saving ovarian cancer research. A heartfelt thank you to everyone who joined us in support of this important cause.